Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats

Molecular Pharmaceutics

Volumn 7, Issue 6, 2010, Pages 1995-2005

  Pang, Zhiqing ^a,b   Feng, Liang ^a,b   Hua, Rongrong ^a,b   Chen, Jun ^a,b   Gao, Huile ^a,b   Pan, Shuaiqi ^a,b   Jiang, Xinguo ^a,b   Zhang, Peng ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Department of Pharmaceutics ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LACTOFERRIN; POLYMER; TETRANDRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIODEGRADABILITY; BLOOD BRAIN BARRIER; CONJUGATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TUMOR LEVEL; ENCAPSULATION; FILM; GLIOMA; GLIOMA CELL; IMAGING SYSTEM; IN VIVO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROGNOSIS; RAT; RIGHT HEMISPHERE; SURVIVAL TIME; TECHNIQUE; TISSUE DISTRIBUTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZYLISOQUINOLINES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GLIOMA; LACTOFERRIN; PARTICLE SIZE; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649961648     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100277h     Document Type: Article

References (41)

1. Colman, H.; Aldape, K. Molecular predictors in glioblastoma Arch. Neurol. 2008, 65 (7) 877-883
2. Lu, C.; Shervington, A. Chemoresistance in gliomas Mol. Cell. Biochem. 2008, 312, 71-78
3. Silbergeld, D. L.; Chicoine, M. R. Isolation and characterization of human malignant glioma cells from histologically normal brain J. Neurosug. 1997, 86 (3) 525-531
4. Juillerat, J. L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles Drug Discovery Today 2008, 13, 1099-1106
5. Marc, C. C. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability Expert Rev. Neurother. 2010, 10 (4) 547-561
6. Oh, K. T.; Baik, H. J.; Lee, A. H.; Oh, Y. T.; Youn, Y. S.; Lee, E. S. The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system Int. J. Mol. Sci. 2009, 10, 3776-3792
7. Ji, B.; Maeda, J.; Higuchi, M. Pharmacokinetics and brain uptake of lactoferrin in rat Life Sci. 2006, 78 (8) 851-855
8. Huang, R. Q.; Ke, W. L.; Liu, Y.; Jiang, C.; Pei, Y. Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain Biomaterials 2008, 29, 238-246
9. Hu, K. L.; Li, J. W.; Shen, Y. H.; Lu, W.; Gao, X. L.; Zhang, Q. Z.; Jiang, X. G. Lactoferrin-conjugated PEG-PLA nanoparticles with improve brain delivery: in vivo and in vitro evaluations J. Controlled Release 2009, 134, 55-61
10. Suzuki, Y. A.; Lopez, V.; Lonnerdal, B. Mammalian lactoferrin receptors: structure and function Cell. Mol. Life Sci. 2005, 62 (22) 2560-2575
11. Maletinska, L.; Blakely, E. A.; Bjornstad, K. A. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low density lipoprotein receptor-related protein Cancer Res. 2000, 60, 2300-2303
12. Uden, E. V.; Carlson, G.; Hyslop, P. Abberrant presenilin-1 expression downregulates LDL receptor-related protein (LRP): Is LRP central to Alzheimer's Disease pathogenesis Mol. Cell. Neurosci. 1999, 14, 129-140
13. Fillebeen, C.; Descamps, L.; Dehouck, M. P. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier J. Biol. Chem. 1999, 274 (11) 7011-7017
14. Demeule, M.; Poirier, J.; Jodoin, J.; Bertrand, Y.; Desrosiers, R. R.; Dagenais, C.; Nguyen, T.; Lanthier, J.; Gabathuler, R.; Kennard, M.; Jefferies, W. A.; Karkan, D.; Tsai, S.; Fenart, L.; Cecchelli, R.; Beliveau, R. High transcytosis of melanotransferrin (p97) across the blood-brain barrier J. Neurochem. 2002, 83, 924-933
15. Pan, W.; Kastin, A. J.; Zankel, T. C.; van Kerkhof, P.; Terasaki, T.; Bu, G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier J. Cell Sci. 2004, 117, 5071-5078
16. Demeule, M.; Currie, J. C.; Bertrand, Y.; Che, C.; Nguyen, T.; Regina, A.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2 J. Neurochem. 2008, 106, 1534-1544
17. Discher, D. E.; Eisenberg, A. Polymer vesicles Science 2002, 297, 967-973
18. Discher, D. E.; Ahmed, F. Polymersomes Annu. Rev. Biomed. Eng. 2006, 8, 323-41
19. Pang, Z. Q.; Lu, W.; Gao, H. L.; Hu, K. L.; Chen, J.; Zhang, Q. Z.; Gao, X. L.; Jiang, X. G.; Zhu, C. Q. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26 J. Controlled Release 2008, 128, 120-127
20. Discher, D. E.; Ortiz, V.; Srinivas, G.; Klein, M. L.; Kim, Y.; Christian, D.; Cai, S.; Photos, P.; Ahmed, F. Emerging applications of polymersomes in delivery: from molecular dynamics to shrinkage of tumors Prog. Polym. Sci. 2007, 32, 838-857
21. Fu, L. W.; Liang, Y. J.; Deng, L. W.; Ding, Y.; Chen, L. M.; Ye, Y. L.; Yang, X. P.; Pan, Q. C. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Chemother. Pharmacol. 2004, 53, 349-356
22. Fu, L. W.; Zhang, Y. M.; Liang, Y. J.; Yang, X. P.; Pan, Q. C. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells Eur. J. Cancer 2002, 38, 418-426
23. Wang, J. C.; Liu, X. Y.; Lü, W. L.; Lee, H. S.; Goh, B. C.; Zhang, Q. The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes Acta Pharm. Sin. 2005, 40 (5) 475-480
24. Van, V. L. E.; Duan, Z.; Seiden, M. V. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer Cancer Res. 2007, 67, 4348-4850
25. Photos, P. J.; Bacakova, L.; Discher, B.; Bates, F. S.; Discher, D. E. Polymer vesicles in vivo: correlations with PEG molecular weight J. Controlled Release 2003, 90, 323-334
26. Olivier, J. C.; Huertas, R.; Lee, H. J.; Calon, F.; Pardridge, W. M. Synthesis of pegylated immunonanoparticles Pharm. Res. 2002, 19, 1137-1143
27. Lu, W.; Tan, Y. Z.; Hu, K. L.; Jiang, X. G. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier Int. J. Pharm. 2005, 295, 247-260
28. Pan, H.; Han, L. M.; Chen, W.; Yao, M.; Lu, W. Y. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes J. Controlled Release 2008, 125, 228-235
29. Lu, W.; Sun, Q.; Wan, J.; She, Z. J.; Jiang, X. G. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration Cancer Res. 2006, 66, 11878-11887
30. Schoch, G.; Seeger, H.; Bogousslavsky, J.; Tolnay, M.; Janzer, R. C.; Aguzzi, A.; Glatzel, M. Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease PLoS Med. 2006, 3 e14
31. Li, S. D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles Mol. Pharmaceutics 2008, 5 (4) 496-504
32. Huwyler, J.; Wu, D.; Pardridge, W. M. Brain drug delivery of small molecules using immunoliposomes Proc. Natl. Acad. Sci. U.S.A. 1996, 93 (24) 14164-14169
33. Kemper, E. M.; Boogerd, W.; Thuis, I.; Beijnen, J. H.; Tellingen, O. V. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours Cancer Treat. Rev. 2004, 30, 415-423
34. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Delivery Rev. 2010. DOI: 10.1016/j.addr.2010.04.009.
35. Schlageter, K. E.; Molnar, P.; Lapin, G. D.; Groothuis, D. R. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties Microvasc. Res. 1999, 58 (3) 312-28
36. Schneider, S. W.; Ludwig, T.; Tatenhorst, L.; Braune, S.; Oberleithner, H.; Senner, V.; Paulus, W. Glioblastoma cells release factors that disrupt blood-brain barrier features Acta Neuropathol. 2004, 107, 272-276
37. Lu, W.; Wan, J.; She, Z.; Jiang, X. G. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle J. Controlled Release 2007, 118 (1) 38-53
38. Cui, J.; Li, C.; Guo, W.; Li, Y.; Wang, C.; Zhang, L.; Zhang, L.; Hao, Y.; Wang, Y. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy J. Controlled Release 2007, 118 (2) 204-15
39. Pardridge, W. M. Brain drug targeting; Cambridge University Press: Cambridge, 1998; p 82.
40. 4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells Int. J. Nanomed. 2008, 3 (2) 277-286
41. Shen, H. L.; Xu, W. L.; Chen, Q. Y. Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription J. Cancer Res. Clin. Oncol. 2010, 136, 659-665